Search Results for: About
New grant will fund substantiating MenaQ7 Vitamin K2 effect on calcium metabolism The Norwegian Research Council has awarded a grant to ex-NattoPharma to fund a 4-year project to document the effects of calcium metabolism in the body based on the presence or absence of Vitamin K2, MK7. The project will utilize ex-NattoPharma’s MenaQ7® Vitamin K2 … Continue reading Norwegian Research Council Grant
New grant will fund substantiating MenaQ7 Vitamin K2 effect on calcium metabolism
The Norwegian Research Council has awarded a grant to ex-NattoPharma to fund a 4-year project to document the effects of calcium metabolism in the body based on the presence or absence of Vitamin K2, MK7. The project will utilize ex-NattoPharma’s MenaQ7® Vitamin K2 as MK-7 and the research part will be conducted at the Maastricht University in the Netherlands in the Department of Biochemistry under the guidance of Dr. Leon Schurgers, Senior Scientist and Associate Professor of Biochemistry at Maastricht and CARIM, the Cardiovascular Research Institute of Maastricht.
In this research, Nattopharma together with the Maastricht University will study the utilisation of calcium in preclinical models for postmenopausal bone loss and chronic kidney failure to determine how supplemental calcium is metabolized in the presence or absence of supplemental vitamin K2, MK7.
“This study will help to provide further evidence that calcium without adequate Vitamin K2 consumption might end up in the soft tissues where it is not wanted, rather than in the bone matrix, where it is needed,” says Dr. Schurgers. In a recent study by “Bolland et al. it was shown that calcium supplementation of postmenopausal women was associated a beneficial effect on bone, but also with increased myocardial infarction, suggesting detrimental effects on the vascular system possibly by increased vascular calcification. As calcium supplementation is needed for bone, the precipitation in the vessel wall needs to be inhibited.”
Vitamin K2’s role as a cardiovascular supporter
Ex-NattoPharma is rightfully excited about this new study, which should add to the evidence confirming Vitamin K2’s role as a cardiovascular supporter, including the ground-breaking three-year interventional study[1] the company sponsored that confirmed adding 180mcg of MenaQ7® Vitamin K2 as MK-7 to one’s daily intake improves arterial health and flexibility.
“This will be the first study that demonstrates K2’s impact on calcium metabolism in vivo; however, we have shown in human studies with healthy participants that the progression of hardening of the arteries can be halted and even regressed,” adds Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer. “Calcium supplement manufacturers must recognize the importance of pairing calcium with Vitamin K2. They cannot ignore the growing body of evidence that K2 is required for the body to properly metabolize and utilize calcium.”
Reference:
1 Knapen MH et al, Braam LAJL, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015 113 5: 1135-1144. doi: 10.1160/TH14-08-0675.
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation. Heart Health ranks as one of the top 3 reasons respondents use dietary supplements. At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering … Continue reading Consumer Survey Shows Interest in Supplements for Artery Health
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation.
Heart Health ranks as one of the top 3 reasons respondents use dietary supplements.
At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering three primary questions:
1. How concerned are people with the health of their heart?
2. Do they believe that hard arteries are a problem that is associated with poor heart health?
3. How willing would they be to take a supplement to improve the health of their heart by preventing (and even reversing) the hardening of their arteries?
Key Findings: Of the 380 individuals surveyed:
• 87% currently take vitamins or supplements to improve their health.
• 25% identify themselves as having a condition associated with heart disease; 40% have someone in their immediate family with a condition associated with heart disease.
• 35% are very concerned that hardening of the arteries will have a negative impact on their heart health.
• 67% of those surveyed (n = 380) would take a supplement shown to stop hardening of the arteries if the supplement carried no side effects and is priced about the same as other heart health supplements.
Bone and Heart Health are the top reasons customers supplement (reason 2 and 3, respectively). When asked how concerned they were about their heart health on a scale of 1-7, 62% rated their level of concern as 5 or greater (38% rated their level of concern 6 or greater).
Of those who indicated that they or their family member currently has a heart condition (n=232),
• 84% are currently taking a prescription medicine (55% would consider taking a prescription)
• 44% are currently taking a supplement (59% would consider taking a supplement)
Of those who indicated that they currently do not have a heart condition (n=148), for those surveyed between 30 and 40 years old, supplements would be their No. 1 action if they developed heart disease.
“Just over one-third of survey participants ranked ‘hardening of the arteries’ as one of the top 3 risk factors associated with heart disease. This is a concern with growing awareness with Americans, but a natural solution to address this concern was not previously available,” said Eric Anderson, senior vice president of global sales and marketing with ex-NattoPharma, exclusive global supplier of MenaQ7® Vitamin K2 as MK-7. “However, our clinical trials have shown that MenaQ7 addresses 2 of the top 3 reasons that health-minded consumers supplement: MenaQ7 not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos. Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”. Biolab … Continue reading Product Launch in Brazil
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos.
Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”.
Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the No. 1 pharmaceutical company for cardiology prescriptions. More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in Vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 Vitamin K2 as MK-7, specifically the cardiovascular benefits.
“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr. Francisco Fonseca.
According to Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are excited about Doiska MenaQ7® arrival in the pharmacies, expected by beginning of August this year. “We are confident the partnership between ex-NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”
Active Lifestylers
The bone and joint market is still expected to be driven by aging populations, but trends like Healthy Aging and Fitter for Longer open the market for younger demographics. Since 2000, views have drastically evolved about the importance of staying active and the role bone/joint health plays in one’s ability to do so.
Bone fractures are an obvious hindrance to staying active. In fact, every 3rd woman and every 5th man over the age of 50 will experience osteoporotic fractures. It is also worth noting that young female athletes have higher fracture risks than male counterparts.
Knowing the intricate balance between Vitamins D3 and K2, and its combined benefits for bone and heart health, a product that aims to support active lifestylers should incorporate both.
Major market penetration kicks off with leading brands Ex-NattoPharma ASA, world leader in vitamin K2 research and development, in collaboratoin with Complementary Medicines Group (CMG) Australia, announces successful penetration into the Australian and New Zealand markets, including supplying major Sponsor brands. This collaboration has resulted in exciting developments. First, Blackmores, Australia’s leading natural … Continue reading MenaQ7® K2 Launched in Australia/New Zealand
Major market penetration kicks off with leading brands
Ex-NattoPharma ASA, world leader in vitamin K2 research and development, in collaboratoin with Complementary Medicines Group (CMG) Australia, announces successful penetration into the Australian and New Zealand markets, including supplying major Sponsor brands.
This collaboration has resulted in exciting developments. First, Blackmores, Australia’s leading natural health brand, will utilize ex-NattoPharma’s MenaQ7® Vitamin K2 in a soon-to-be-released product that will be sold both online and through brick-and-mortar stores across Australia. BioCeuticals, supplier of high-quality practitioner-specific nutritional and therapeutic supplements, has also signed on to use its MenaQ7® Vitamin K2 in an upcoming product.
Another product concept released
In addition, another new product concept has already been released: Essential Nutrition Vitamin K2, a standalone bone health product featuring ex-NattoPharma’s MenaQ7® Vitamin K2 as MK-7, the only clinically validated and patented vitamin K2 as MK-7. The product is currently being sold online at www.essentialnutrition.net.au, and it will in November 2014 be sold exclusively through Go Vita, a 150-store retail natural products chain.
“Bone health is a serious concern, and the introduction of MenaQ7 Vitamin K2 to the Australian and New Zealand markets has been significant. We are energized,” says Craig Fallshaw, CMG Founder. “It is so validating to bring the only clinically validated, patented vitamin K2 as MK-7 to these markets.” In close collaboration with ex-NattoPharma ASA, CMG has leveraged relationships to bring the current product offering to market, as well as other opportunities for future products, and increase awareness of this important bone health ingredient. Most recently, CMG was a sponsor of the Complementary Medicines Australia (CMA) National Conference and 15th Annual Awards Dinner on October 30, 2014, where it was named the 2014 Wholesaler/Distributor of the Year.
“We are very pleased to make significant progress in Australia and New Zealand introducing our proprietary, patented, and clinically proven MenaQ7® Vitamin K2 as MK-7,” says Hogne Vik, CEO of ex-NattoPharma ASA. “We look forward to a long and successful relationship with CMG and its partner groups.”
About CMG
Complementary Medicines Group (CMG) is a service provider to the complementary medicine, food and over-the-counter pharmaceuticals industries. Offering raw materials, contract manufacturing, and marketing services, CMG was named the Complementary Medicines Australia 2011 Manufacturer, Wholesaler, or Distributor of the Year, and the 2014 Wholesaler/Distributor of the Year. For more information, visit cmgrouponline.com/au
As a complement to its award-winning Beginner’s DHA for Kids featuring MenaQ7® Vitamin K2, Wiley’s Finest Fish Oil introduced its Adult formula at Expo West 2017. And the company’s catchy campaign – “Climb the Peak of Health” – has been a huge success, landing on Times Square (NY, NY). “Playing off the fact that … Continue reading “Climb to the Peak of Health” Message in Times Square
As a complement to its award-winning Beginner’s DHA for Kids featuring MenaQ7® Vitamin K2, Wiley’s Finest Fish Oil introduced its Adult formula at Expo West 2017. And the company’s catchy campaign – “Climb the Peak of Health” – has been a huge success, landing on Times Square (NY, NY).
“Playing off the fact that Vitamin K2 is both a key nutrient in this formula and the name of the second highest mountain on earth, we decided to launch this product with the campaign theme of ‘Climb the Peak of Health’. We felt it would be a fun and inspirational way to engage our valued customers and encourage them to rise to the heights of good health,” explains Wiley’s Finest™ CEO Sam Wiley.
The new product combines both 500mg of concentrated EPA and DHA Omega-3 from Alaska Pollock Fish Oil with a meaningful dosage of MenaQ7® K2 per serving (80mcg). Wiley’s opted for this dose after reviewing studies that showed MenaQ7® K2 delivered positive health benefits at just 45mcg per day.
To learn more about the product, click here.
